ZVRA · Zevra Therapeutics, Inc. · Stock research

Current Thesis

The EU leg is dead and the name has been re-underwritten on US commercial execution. Q2 2026, reported 2026-08-05: total net revenue $39.663M against $33.572M consensus, MIPLYFFA net revenue $30.2M (+40% YoY, +23% over Q1's $24.6M), adjusted net income $15.2M / $0.25 per diluted share versus $0.14 consensus, GAAP net income $8.8M / $0.14. Price closed $11.32 on 2026-08-14, effectively retracing the entire 2026-07-24 CHMP gap-down session (that day ranged $8.52–$11.59 and closed near $9.47). What an investor is buying now is a US-only, cash-generative single-product rare-disease franchise whose sequential revenue is still climbing while the European path sits in re-examination with an outcome guided to Q4 2026 — a fundamentals leg, not the patent/EU-expansion story that ran in June.

Bullish and bearish views on Zevra Therapeutics, Inc.

The model's bull view on Zevra Therapeutics, Inc. (ZVRA), in brief: MIPLYFFA re-accelerated rather than plateaued: $30.2M in Q2 versus $24.6M in Q1 and +40% YoY (Q2 2026 release, 2026-08-05). The bear view: $9.0M of the $39.7M Q2 net revenue came from expanded-access-program reimbursements, plus $0.2M OLPRUVA and $0.3M of past-due AZSTARYS royalties. Both cases follow in full.

Bull Case

• MIPLYFFA re-accelerated rather than plateaued: $30.2M in Q2 versus $24.6M in Q1 and +40% YoY (Q2 2026 release, 2026-08-05). The launch curve had been the central open question after the 2026-07-24 CHMP rejection.
• The quarter beat on both lines: revenue $39.663M vs $33.572M consensus, adjusted EPS $0.25 vs $0.14 (Benzinga wire, 2026-08-05). Profitability is reported, not projected.
• Cash built inside the quarter: $260.2M at 2026-06-30 versus $236.8M at 2026-03-31, debt-free after the March 2026 repayment of $61.9M. Management stated resources are sufficient to execute strategic priorities independent of the capital markets (Q2 2026 release).
• It is the same evidence class the CHMP said was insufficient.
• Sell-side has not abandoned the name post-rejection: Citizens raised its target to $28 with a Market Outperform on 2026-08-06; Guggenheim maintained Buy while cutting to $23 on 2026-08-07.
• US exclusivity is untouched by the EU decision: Orange Book patent 11,707,456 (expiry 2041-11-19), listed 2026-06-08, plus a USPTO patent-term-extension filing.

Bear Case

• $9.0M of the $39.7M Q2 net revenue came from expanded-access-program reimbursements, plus $0.2M OLPRUVA and $0.3M of past-due AZSTARYS royalties. The recurring commercial product line is the $30.2M, and the EAP line is tied to a program whose future depends on the EU pathway.
• Patient-add cadence is small in absolute terms: 14 new prescription enrollment forms in Q2 against 184 cumulative since the September 2024 launch, with payer coverage flat at 69% of covered lives. NPC is ultra-rare and the US pool is finite; a quarter of high sequential revenue growth on 14 net new forms is a narrow base.
• The efficacy-grounds rejection is the hardest kind to reverse. The company has requested re-examination (confirmed in the Q2 release), but the CHMP is being asked to revisit the same efficacy conclusion it reached on 2026-07-24, and the outcome is guided to Q4 2026.
• DiSCOVER is event-driven, not calendar-driven: 66 patients enrolled and 3 confirmed events as of 2026-06-30, against 28 events required to trigger the interim analysis. That is not a datable catalyst on any near horizon.
• Analyst dispersion widened rather than narrowed after the print — $23 from Guggenheim on 2026-08-07 against $28 from Citizens on 2026-08-06 — and both remain far above the 2026-08-14 close of $11.32, which is the configuration that existed before the June-to-July round trip.
• Price is still 23.3% below the $14.75 52-week high with a 3-month return of only +2.8%: the July drawdown consumed a full quarter of trend.

Setup & Price Structure

The narrative is accelerating, dated to the 2026-08-05 Q2 print and the 2026-08-08 session in which the stock rose 21.6% on MIPLYFFA uptake and the new real-world publication, followed by target actions from two brokers on 2026-08-06 and 2026-08-07. Attention is fresh and the headlines are new. The qualifier matters: this is a recovery leg inside a structure that broke on 2026-07-24, not a continuation of the June trend.

Observable structure: the 2026-08-14 close of $11.32 sits just under the $11.59 intraday high of the CHMP-opinion session and just under the $11.50 shelf that held from the June patent listing until 2026-07-24. That shelf is the line the recovery has not yet converted into support on a closing weekly reading. Below it, the reference marks are the 2026-07-24 close near $9.47 and that session's $8.52 low; above it, the unfilled zone runs toward the $14.75 52-week high.

Crowding and positioning observables, stated as observables: RSI(14) was 71.5 at 2026-08-14, an overbought reading reached after a single +21.6% session; retail-facing "why is it up" coverage clustered on 2026-08-08; the earnings event is behind rather than ahead, so there is no imminent print to compress the move; and no company-specific dated catalyst falls inside the next 30 days. Insider transactions and share-issuance activity in the window are not in the evidence reviewed here, so no claim is made either way.

Catalyst Calendar (next 30 days)

• No dated company catalyst falls between 2026-08-16 and 2026-09-15. The Q2 print (2026-08-05) has passed and the next scheduled financial event is the Q3 report.
• ~2026-09-22 (est.) — detailed grounds for the CHMP re-examination due, on the standard 60-day clock from the 2026-07-24 negative opinion. The company confirmed in the Q2 release that re-examination has been requested. This sits just beyond the 30-day window.
• ~2026-11-05 (est.) — Q3 2026 results. The comparison that matters is MIPLYFFA net revenue against Q2's $30.2M, the enrollment-form count against 184 cumulative, and whether the $9.0M expanded-access reimbursement line holds.
• Q4 2026 (company-guided, no date set) — CHMP re-examination opinion on arimoclomol for NPC.

Elapsed catalysts

• H2 2026 (company-guided, no date set) — continued FDA engagement on pathways to accelerate celiprolol clinical development, per the 2026-08-05 corporate update. (passed 21d ago)

What Would Change Our Mind

The recovery leg depends on the $11.50 pre-CHMP shelf converting from resistance into support; a failure there that carries price back beneath the 2026-07-24 selloff close would mean the Q2 beat bought a three-week bounce and nothing structural. Gradeable version: a daily close below $9.47 surrenders the entire post-print recovery and re-opens the $8.52 low from the CHMP session.

On fundamentals, the specific datapoint that would break the re-underwriting is a Q3 print (~2026-11-05, est.) with MIPLYFFA net revenue below Q2's $30.2M, or a collapse in the $9.0M expanded-access reimbursement line without commercial revenue absorbing it — that combination would show the US engine, which is now the whole thesis, decelerating on a finite patient pool.

On the regulatory side, a CHMP re-examination opinion in Q4 2026 that reaffirms the negative conclusion closes the EU market for the foreseeable term and leaves valuation resting entirely on a few hundred treated US patients plus $260.2M of cash. Conversely, a positive re-examination would restore the expansion story the June trade was built on — that is the low-probability upside branch the current price does not appear to be paying for, given both live targets ($23, $28) sit roughly double the 2026-08-14 close.

Correlation Notes

• Idiosyncratic first: the 2026-07-24 CHMP opinion and the 2026-08-05 print each moved the stock double digits on company-specific news, so sector beta explains little of the last month.
• With no dated catalyst until late September, drift is likely to be set by small-cap biotech risk appetite (XBI) and rate expectations rather than by news flow. This is an inference from the empty calendar, not a measured beta.
• Read-through group: US-listed single-product rare-disease commercial-stage names. A CHMP re-examination outcome here is a data point on how the committee treats real-world-evidence packages in ultra-rare indications generally, and would be read across.
• No AI, semiconductor or industrial-power linkage — this name does not participate in those rotations.